Management tracks: Gilead taps Dickinson for CFO job; plus Checkmate, BiomX, Anixa and Trio

Andrew Dickinson, EVP, corporate development and strategy of Gilead Sciences Inc. (NASDAQ: GILD), will become CFO, effective Nov. 1. He succeeds Robin Washington, who is retiring, while retaining responsibility for corporate development and strategy. Dickinson orchestrated Gilead's $12 billion acquisition of Kite Pharma Inc. in 2017 as well as this year's 10-year collaboration with Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) (see "How Gilead Deal Positions Galapagos to Become Europe’s Next Big Biotech")

Immuno-oncology company Checkmate Pharmaceuticals Inc. hired James Wooldridge as CMO and Steven Hamburger as VP of regulatory affairs. Wooldridge was CMO at Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) while Hamburger was VP, regulatory affairs and quality assurance at Tarveda Therapeutics Inc. ...